Quick Facts

• Primary Use: Management of diabetes mellitus in cats and dogs.
• Therapeutic Goal: Reduction of high blood sugar (hyperglycemia) and associated clinical indicators.

ProZinc is a therapeutic option used in the management of diabetes mellitus in both cats and dogs. The primary use of this prescribed medication is to assist in the sustained reduction of high blood sugar (hyperglycemia) in the patient. This action is intended to support the body's natural processes of glucose utilization.

The essential benefit of appropriate use is the management of clinical signs that are associated with high blood sugar levels. These signs may include excessive thirst (polydipsia) and excessive urination (polyuria). The medication is part of a comprehensive, veterinary-directed plan to help attain and maintain adequate glycemic control and promote overall patient well-being.

Controlling blood glucose levels is a key element of the long-term management of this endocrine condition. A licensed veterinarian must determine the appropriateness of this medication for an individual patient.

Eligibility Map: Who can and cannot use ProZinc — Official Regulatory Information

The official regulatory profile for ProZinc establishes which animal populations are eligible and which are restricted or formally contraindicated.

Eligibility Scope

Populations for whom use is allowed (as stated in label): Cats and Dogs with diabetes mellitus for the reduction of hyperglycemia and associated clinical signs.

Populations for whom use is contraindicated: Animals with known hypersensitivity to protamine zinc recombinant human insulin or any other ingredients; animals currently experiencing episodes of hypoglycemia (low blood sugar); and for the acute management of diabetic ketoacidosis (DKA).

Age-related eligibility rules: Safety and effectiveness have not been evaluated in kittens or puppies.

Condition-specific eligibility rules: Animals presenting with severe ketoacidosis, anorexia, or vomiting require stabilization with short-acting insulin and supportive care prior to initiating ProZinc therapy. Use of concomitant Glucocorticoids or Progestogens should be avoided.

Pregnancy and lactation eligibility status (if explicitly documented): The safety and effectiveness in breeding, pregnant, and lactating animals has not been evaluated. Use in these populations is subject to a benefit-risk assessment.

Resulting Eligibility Structure

Official regulatory documents define the eligible population as dogs and cats with diabetes mellitus. Non-eligibility is established through formal contraindications tied to acute metabolic conditions (hypoglycemia/DKA) and hypersensitivity, and by the classification that safety and effectiveness have not been evaluated for all juvenile and reproductive populations.

Interactions with other medicines and products

The interaction profile for ProZinc (protamine zinc recombinant human insulin) is defined by its core activity as an insulin product and its susceptibility to substances that alter blood glucose levels. All interaction information is based strictly on regulatory documents.

Contraindicated Combinations and States

Administration of ProZinc is formally contraindicated during existing episodes of hypoglycemia (low blood sugar). This restriction is based on the immediate and severe pharmacodynamic outcome of combining insulin with this metabolic state. Use is also contraindicated in patients with a known hypersensitivity to the active substance or any excipients.

Pharmacodynamic Interference

Co-administration with specific medicinal product classes can exert an antagonistic effect on the activity of insulin, as described in regulatory labeling.

Confounding Factors Affecting Insulin Requirements

Official documents recognize that factors external to drug-drug interactions can influence the required insulin activity. These factors, which include concurrent diseases (e.g., infectious or inflammatory disorders), stressful events, and significant changes in diet (such as the feeding of a high protein/low carbohydrate diet), are officially noted as potential sources of altered insulin requirements.

ProZinc is an aqueous suspension of protamine zinc recombinant human insulin, a long-acting formulation designed for delayed systemic absorption. Following subcutaneous injection, the insulin is initially aggregated as large complexes with zinc and the polycationic protein protamine, forming a subcutaneous depot. Proteolytic tissue enzymes gradually degrade the protamine component, enabling the slow dissolution and systemic absorption of the insulin hexamers, dimers, and ultimately, bioactive monomers. Once in the systemic circulation, the insulin monomers function as an agonist, binding to the ubiquitous insulin receptor (IR) on the cell membranes of target tissues, primarily liver, muscle, and adipose tissue. Receptor activation initiates a complex intracellular tyrosine phosphorylation cascade, including the Insulin Receptor Substrate (IRS) proteins. This signaling culminates in the translocation of Glucose Transporter type 4 (GLUT4) vesicles from the cytoplasm to the cell membrane in muscle and adipose tissue, increasing cellular glucose uptake. Concurrently, insulin signaling suppresses hepatic gluconeogenesis and glycogenolysis and promotes glycogen synthesis (glycogenesis) in the liver and muscle. The system-level physiological consequence is a sustained modulation of glucose and fat metabolism, including a reduction in circulating blood glucose concentration.

How to Use ProZinc

ProZinc (Protamine Zinc Recombinant Human Insulin) is a 40 International Units (IU) per milliliter aqueous suspension administered exclusively via subcutaneous injection on the back of the neck or side of the animal. Accurate dosing mandates the use of a U-40 insulin syringe; utilizing any other syringe type will result in an incorrect dose.

Prior to drawing the suspension, the vial must be gently rolled to ensure the insulin is uniformly mixed; vigorous agitation or shaking is explicitly forbidden. The injection should be timed to occur concurrently with or immediately after a meal.

Official Dosing Regimens

The standard starting regimens vary by species.

If a dog requires a transition to a twice-daily schedule due to inadequate duration of action, each of the two doses should be adjusted to be approximately 25% less than the once-daily dose required for stability. The product is contraindicated for the acute management of diabetic ketoacidosis (DKA) and is intended solely for long-term management requiring veterinary supervision and periodic dose adjustment.

ProZinc: Recent Clinical Evidence

The overview of research for ProZinc focuses on field studies evaluating its use in managing high blood sugar (hyperglycemia) in diabetic cats and dogs.

Evidence for Use in Hyperglycemia in Cats

The research exploring ProZinc's use in hyperglycemia was conducted through multi-center field studies. These investigations are mainly open-label, and studies included a population of client-owned cats with diabetes, covering both those who were newly diagnosed and those who were considered to be poorly regulated on previous insulin regimens.

Study Designs and Measured Outcomes for Feline Patients

Studies monitored changes in biomarkers of glycemic status, such as the concentration of serum fructosamine and the mean blood glucose level. Studies examined clinical outcomes such as excessive thirst (polydipsia) and excessive urination (polyuria). Findings describe patterns observed in the studies related to the frequency with which certain predefined glycemic targets were met, as reported in regulatory documents.

Evidence for Use in Hyperglycemia in Dogs

The research base for ProZinc for hyperglycemia in dogs is founded on large-scale field studies. These investigations were also conducted across multiple centers and were baseline-controlled, meaning each dog's outcomes were compared against their own status before the start of the study.

Study Designs and Measured Outcomes for Canine Patients

Research examined outcomes related to systemic or functional imbalance by monitoring blood biomarkers of glycemic status, including the mean blood glucose, the minimum blood glucose (nadir), and fructosamine levels. Studies examined clinical outcomes such as patterns related to thirst, urination, and changes in body weight.

Evidence Gaps and Areas of Research Uncertainty

A key limitation in the research is that much of the core evidence is derived from baseline-controlled, open-label field studies, and comparative evidence is lacking from large, randomized, blinded controlled trials (RCTs). Furthermore, long-term effects are not fully established, as follow-up durations were limited in key feline trials. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References NIH: Insulin Pharmacology and Mechanisms of Action (Reference for definition and recombinant origin of insulin human)

Common questions about ProZinc (FAQ)

Q: How does the 'protamine zinc' component affect how ProZinc works in the body?

ProZinc is formulated by combining insulin with protamine and zinc, causing the components to form crystalline complexes. After the subcutaneous injection, tissue enzymes gradually break down the protamine, allowing the insulin to be absorbed slowly. This specialized process is what provides the drug's extended duration of action.

Q: How long is the typical duration of action for a single dose of ProZinc?

The typical duration of action is variable depending on the species. In clinical studies involving cats, the glucose-lowering effect generally lasted for a minimum of 9 hours. The product information for dogs notes the duration of action is also variable, ranging from 12 to over 24 hours in experimental studies.

Q: How quickly can effects be expected after starting ProZinc?

Achieving the full intended effect of any insulin therapy requires an equilibration phase that spans several days. Studies and official information indicate that improvements in common clinical signs, such as excessive thirst or urination, were often observed within 7 to 45 days of starting ProZinc, depending on the individual response.

Q: What should a user do if white clumps are visible after gently rolling the vial?

Insulin suspensions can sometimes form clumps or visible white particles, which indicates that the product may be damaged or unstable. Regulatory documents explicitly state that the product must not be used if these visible agglomerates persist after gently rolling the vial. Regulatory documents indicate the product should be discarded and replaced.

Q: Is it important to rotate the location where ProZinc is injected?

The official product information lists the recommended sites for subcutaneous injection. Although not explicitly mandated as an instruction, rotating the injection site is a general clinical principle that may minimize the risk of localized skin reactions or changes at the injection area.

Q: Are there specific types of dietary changes that could alter the need for ProZinc?

Yes, significant changes in diet are noted in official documents as factors that may influence the required insulin activity. Regulatory documentation specifically highlights that feeding cats a high protein/low carbohydrate diet may alter their insulin needs and could require a dose adjustment.

Q: Is it common for the ProZinc dose to require adjustment over time?

Yes, the official documents state that ProZinc is intended for long-term management that requires veterinary supervision and periodic dose adjustment. The dose may need to be adjusted based on clinical signs, monitoring results, changes in diet, body weight, or the presence of concurrent diseases.

Q: What is the Somogyi effect, and is it a concern with ProZinc?

The Somogyi effect, or rebound hyperglycemia, is a clinical situation where an insulin overdose causes blood sugar to drop too low, leading to a subsequent rise in sugar levels. Regulatory documents mention that veterinarians may need to consider dose reductions if they suspect this effect is occurring.

Q: Are there any reported long-term adverse health issues associated with ProZinc therapy?

The evidence base for the product primarily relies on field studies with limited follow-up durations. Regulatory documents therefore state that the long-term effects are not fully established. Safety parameters were typically measured for up to approximately 182 days in the large clinical trials.

Q: What happens if ProZinc is accidentally shaken vigorously instead of rolled?

The official regulatory instructions strictly state to gently roll the vial and never shake or vigorously agitate it. Shaking may alter the physical integrity of the insulin, which could potentially reduce effectiveness and lead to an incorrect dose being withdrawn.

Q: What are the risks of using a U-100 syringe instead of a U-40 syringe for ProZinc?

ProZinc is a U-40 concentration (40 units per mL). Regulatory documents explicitly warn that using any syringe other than a U-40 syringe will result in incorrect dosing. This creates the risk of accidentally administering an incorrect dose, which could result in an overdose.

Q: What should be done if a scheduled injection is accidentally missed?

If an injection is missed, it is advised not to repeat the injection immediately or attempt to double-up on the next dose. Official guidance advises to wait until the next regularly scheduled dose is due. If the animal is not eating or is unwell, contact a veterinarian for guidance.

Q: What evidence themes are generally reported in research for ProZinc?

The research primarily focuses on field studies that examine changes in biomarkers of glycemic status, such as blood glucose and fructosamine levels. Studies also report on improvements in clinical signs associated with high blood sugar, such as excessive thirst and urination.

Q: What percentage of treated cats or dogs show improvement in clinical signs with ProZinc?

Clinical trial data published in regulatory sources describe the following results: In a cat field trial, most cats showed improvement in clinical signs within 45 days. In a key dog study, 90% showed improvement in excessive urination and 88% in excessive thirst over the study duration.

Q: Has the effectiveness of ProZinc been evaluated and reported across different breeds?

The core evidence for ProZinc comes from multi-center field studies involving client-owned animals, which would naturally include a range of breeds. However, the regulatory documentation does not provide a formal evaluation or breakdown of effectiveness specifically by breed.

Q: Is ProZinc considered a treatment for all types of diabetes mellitus?

ProZinc is indicated for the management and reduction of hyperglycemia in diabetic cats and dogs. However, regulatory documents state it is contraindicated and should not be used for the acute management of diabetic ketoacidosis (DKA), a severe form of the disease.

Q: What should be done if an accidental human injection of ProZinc occurs?

Accidental self-injection is a serious event that can induce clinical signs of hypoglycemia. Regulatory safety documents advise that the person should seek medical advice immediately and show the package leaflet or label to the treating physician.

Q: What are the correct temperature and conditions for storing ProZinc?

ProZinc must be stored in an upright position under refrigeration between 36 F and 46 F (2 C and 8 C). The vial must be kept in its outer carton to protect the contents from light and must not be frozen.

ProZinc must be stored and handled according to specific, documented regulatory requirements to ensure product stability.

Storage Conditions and Temperature

The product must be stored under refrigeration at a temperature between 36 F and 46 F (2 C and 8 C). The vial must be stored in an upright position in its outer carton to protect the contents from light. Do not freeze the product, and it must be discarded if freezing occurs.

Stability and Handling

Unused portions must be discarded after these time limits. Keep this medicine out of the reach of children.

Disposal

All unused product and waste materials must be disposed of in accordance with local requirements. Medicines should not be disposed of via wastewater or household waste. Used needles and syringes must be placed immediately in a proper sharps disposal container.